SG11201808538QA - Trans-splicing rna (tsrna) - Google Patents
Trans-splicing rna (tsrna)Info
- Publication number
- SG11201808538QA SG11201808538QA SG11201808538QA SG11201808538QA SG11201808538QA SG 11201808538Q A SG11201808538Q A SG 11201808538QA SG 11201808538Q A SG11201808538Q A SG 11201808538QA SG 11201808538Q A SG11201808538Q A SG 11201808538QA SG 11201808538Q A SG11201808538Q A SG 11201808538QA
- Authority
- SG
- Singapore
- Prior art keywords
- tsrna
- trans
- splicing rna
- splicing
- rna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201605586 | 2016-04-01 | ||
| PCT/SG2017/050183 WO2017171654A1 (fr) | 2016-04-01 | 2017-03-31 | Arn de transépissage (tsrna) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808538QA true SG11201808538QA (en) | 2018-10-30 |
Family
ID=59966148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808538QA SG11201808538QA (en) | 2016-04-01 | 2017-03-31 | Trans-splicing rna (tsrna) |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11517583B2 (fr) |
| EP (1) | EP3436590A4 (fr) |
| JP (2) | JP7229467B2 (fr) |
| CN (1) | CN109642241B (fr) |
| AU (1) | AU2017240703B2 (fr) |
| SG (1) | SG11201808538QA (fr) |
| WO (1) | WO2017171654A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021076656A1 (fr) * | 2019-10-15 | 2021-04-22 | University Of Massachusetts | Trans-épissage d'arn amélioré par éditeur d'arn |
| CA3168903A1 (fr) * | 2020-02-07 | 2021-08-12 | University Of Rochester | Assemblage et expression d'arn a mediation par ribozyme |
| GB202102118D0 (en) | 2021-02-15 | 2021-03-31 | Cambridge Entpr Ltd | RNA Trans-Splicing molecule |
| GB202108855D0 (en) | 2021-06-21 | 2021-08-04 | Cambridge Entpr Ltd | Methods of eukaryotic gene expression |
| CN113584169A (zh) * | 2021-07-28 | 2021-11-02 | 南京大学 | 一种与肝癌相关的血清tsRNA标志物、探针及其应用 |
| KR20240052034A (ko) * | 2021-09-03 | 2024-04-22 | 태시트 테라퓨틱스, 인코포레이티드 | 스플라이세오솜 구성요소의 동원을 통한 rna 편집 |
| WO2023140792A2 (fr) * | 2022-01-18 | 2023-07-27 | National University Of Singapore | Arn de transépissage (arnts) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU730305B2 (en) * | 1995-12-15 | 2001-03-01 | Intronn Llc | Therapeutic molecules generated by trans-splicing |
| US6280978B1 (en) * | 1995-12-15 | 2001-08-28 | Intronn Holdings, Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| DE10139492B4 (de) * | 2001-08-13 | 2004-06-09 | Eul, Joachim, Dr. | Verfahren zur Reparatur einer mutierten RNA aus einer gendefekten DNA und zum gezielten Abtöten von Tumorzellen durch RNA-Transspleißen sowie Verfahren zum Nachweis von natürlich-transgespleißter zellulärer RNA |
| JP4475944B2 (ja) * | 2002-04-30 | 2010-06-09 | アイコン・ジェネティクス・ゲーエムベーハー | トランススプライシングに基づく増幅ベクター |
| AU2003237449A1 (en) * | 2002-06-05 | 2003-12-22 | Virxsys Corporation | Spliceosome mediated RNA trans-splicing and correction of factor VIII genetic defects |
| EP1579004B1 (fr) * | 2002-10-23 | 2010-06-16 | VIRxSYS Corporation | Procedes de criblage destines a identifier des molecules de pre-trans-epissage efficaces |
| US7192709B2 (en) | 2004-03-15 | 2007-03-20 | Digigenomics Co., Ltd. | Methods for identification, assessment, prevention, and therapy of cancer |
| KR100958293B1 (ko) * | 2008-03-27 | 2010-05-19 | 단국대학교 산학협력단 | 테오필린에 의해 표적 특이적 ｒｎａ 치환 활성이 조절되는알로스테릭 트랜스―스플라이싱 그룹 ｉ 리보자임 |
| KR20110036996A (ko) * | 2009-10-05 | 2011-04-13 | 전남대학교산학협력단 | 편평세포암 진단 마커인 ｈｏ-1 및 이의 용도 |
| WO2012056441A1 (fr) * | 2010-10-28 | 2012-05-03 | Nanodoc Ltd. | Compositions et procédés pour le clivage spécifique d'arn exogène dans une cellule |
| EP2742128A4 (fr) * | 2011-08-12 | 2015-03-18 | Virxsys Corp | Compositions et procédés pour l'induction de l'apoptose |
| KR101293620B1 (ko) | 2011-08-19 | 2013-08-13 | 국립암센터 | 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도 |
| GB201219762D0 (en) * | 2012-11-02 | 2012-12-19 | Bauer Johann | A RNA trans-splicing molecule (RTM) for use in the treatment of cancer |
| KR101429696B1 (ko) * | 2012-11-21 | 2014-08-13 | 국립암센터 | 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도 |
| US20140283156A1 (en) * | 2013-03-14 | 2014-09-18 | Cold Spring Harbor Laboratory | Trans-splicing ribozymes and silent recombinases |
-
2017
- 2017-03-31 EP EP17776008.9A patent/EP3436590A4/fr active Pending
- 2017-03-31 SG SG11201808538QA patent/SG11201808538QA/en unknown
- 2017-03-31 WO PCT/SG2017/050183 patent/WO2017171654A1/fr active Application Filing
- 2017-03-31 CN CN201780034177.5A patent/CN109642241B/zh active Active
- 2017-03-31 US US16/090,226 patent/US11517583B2/en active Active
- 2017-03-31 JP JP2018551404A patent/JP7229467B2/ja active Active
- 2017-03-31 AU AU2017240703A patent/AU2017240703B2/en active Active
-
2022
- 2022-11-10 US US17/984,846 patent/US20240075051A1/en active Pending
-
2023
- 2023-01-30 JP JP2023011523A patent/JP2023055809A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019509756A (ja) | 2019-04-11 |
| AU2017240703A1 (en) | 2018-10-18 |
| EP3436590A1 (fr) | 2019-02-06 |
| EP3436590A4 (fr) | 2019-12-04 |
| CN109642241A (zh) | 2019-04-16 |
| WO2017171654A1 (fr) | 2017-10-05 |
| US20190111072A1 (en) | 2019-04-18 |
| US11517583B2 (en) | 2022-12-06 |
| US20240075051A1 (en) | 2024-03-07 |
| AU2017240703B2 (en) | 2020-05-21 |
| CN109642241B (zh) | 2023-06-27 |
| JP2023055809A (ja) | 2023-04-18 |
| JP7229467B2 (ja) | 2023-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201905396B (en) | Trans-replicating rna | |
| IL280941A (en) | Modified double helix RNA materials | |
| ZA201905536B (en) | Methods for providing single-stranded rna | |
| EP3256020A4 (fr) | Étui de transport | |
| EP3360426A4 (fr) | Agent d'amélioration de produits alimentaires | |
| SG11201808538QA (en) | Trans-splicing rna (tsrna) | |
| IL254379A0 (en) | Solid rocket motors | |
| ZA202001649B (en) | Rna molecules | |
| EP3395436A4 (fr) | Microréacteur | |
| IL257500A (en) | Altered cullin1 gene | |
| GB201517241D0 (en) | DNA modification | |
| EP3363449A4 (fr) | Agent de renforcement musculaire | |
| EP3265558A4 (fr) | Solutions d'arn stabilisées | |
| GB2537722B (en) | Booklet | |
| EP3295959A4 (fr) | Introduction du gène cmlck | |
| SG11201804610RA (en) | Marking-out aid | |
| GB201506040D0 (en) | Bioremediation | |
| GB201608944D0 (en) | Gene Tharapy | |
| GB201522693D0 (en) | Word sequence representation | |
| GB201500910D0 (en) | Vizzy vowels | |
| AU2015901715A0 (en) | Improved Camber-Inducer | |
| AU2015900527A0 (en) | Improved Decender |